


A Great Leap for Intestinal Research: 20 YEARS AND BEYOND

Curriculum Vitae

Personal Information		
Title (i.e. Pf., Dr., etc.)	Dr	
Name (First name Middle name Last name)	Peter Irving	
Degree (i.e. MD, Msc, PhD, etc.)	MBBS MA MD FRCP	
Country	UK	
Affiliation	Guy's and St Thomas' Hospital London King's College London	
Educational Background		
<p>Dr Irving trained in medicine at Cambridge University and The London Hospital Medical College, from where he graduated with distinction. He trained in gastroenterology in London before undertaking his coctoral research relating to platelet-leucocyte interaction an IBD. Subsequently, he undertook a fellowship in Melbourne, Australia with Professor Peter Gibson before returning to the UK to take up a Consultant position.</p>		
Professional Experience		
<p>He has a large IBD practice with his unit caring for over 5000 patients with more than 1500 on advanced therapies. He has built a large clinical trials programme and has a number of active research interests in translational research and clinical IBD. He is currently supported by an MRC grant related to developing regulatory T cell therapy for IBD</p>		
Professional Organizations		
<p>He has formerly been a member of the BSG IBD Committee, Chair of the Education Committee of ECCO and ECCO e-Learning Ambassador and currently sits on the UEG Education Committee.</p>		

A Great Leap for Intestinal Research: 20 YEARS AND BEYOND

Main Scientific Publications

He has published widely in IBD including several books, book chapters and over 200 peer-reviewed articles.

[Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives.](#)

Irving PM, Gecse KB. *Gastroenterology*. 2022 Apr;162(5):1512-1524

[An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.](#)

Luber RP, O'Neill R, Singh S, Sharma E, Cunningham G, Honap S, Meade S, Ray S, Anderson SH, Mawdsley J, Sanderson JD, Samaan MA, Arkir Z, **Irving PM**. *Aliment Pharmacol Ther*. 2021 Sep;54(5):678-688.

[A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling.](#)

Goldberg R, Clough JN, Roberts LB, Sanchez J, Kordasti S, Petrov N, Hertweck A, Lorenc A, Jackson I, Tasker S, Appios A, Omer O, Parkes M, Prescott N, Jenner RG, **Irving PM**, Lord GM. *J Crohns Colitis*. 2021 Dec 18;15(12):2054-2065

[Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel.](#)

Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F, Cooney R, Dart RJ, Galloway J, Gaya DR, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees CW, Limdi JK, Lindsay JO, Patel K, Powell N, Murray CD, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan MA, **Irving PM**. *Gut*. 2020 Oct;69(10):1769-1777

[Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.](#)

Samaan MA, Cunningham G, Tamilarasan AG, Beltran L, Pavlidis P, Ray S, Mawdsley J, Anderson SH, Sanderson JD, Arkir Z, **Irving PM**. *Aliment Pharmacol Ther*. 2020 Jul;52(2):292-302.

[Regulatory T-cell therapy in Crohn's disease: challenges and advances.](#)

Clough JN, Omer OS, Tasker S, Lord GM, **Irving PM**. *Gut*. 2020 May;69(5):942-952